Lipid lowering and aortic valve disease

Current Atherosclerosis Reports

Volumn 11, Issue 5, 2009, Pages 377-383

  Olsson, Anders G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; PLACEBO; PROTEIN P42; ROSUVASTATIN;

AORTA VALVE STENOSIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; AORTIC VALVE STENOSIS; DISEASE PROGRESSION; HUMANS; LIPIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 68649126046     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0057-z     Document Type: Review

References (27)

1. Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
2. Hudgins LC, Kleinman B, Scheuer A, et al.: Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1199-1204.
3. Tanaka K, Sata M, Fukuda D, et al.: Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005, 46:134-141.
4. Aronow W: Valvular aortic stenosis in the elderly. Cardiol Rev 2007, 15:217-225.
5. Bonow RO, Carabello BA, Chatterjee K, et al.: 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52:e1-e142.
6. GrDve AM, Wachtell K: Review: does lowering cholesterol have an impact on the progression of aortic stenosis? Ther Adv Cardiovasc Dis 2008, 2:277-286.
7. Hakuno D, Kimura N, Yoshioka M, Fukuda K: Molecular mechanisms underlying the onset of degenerative aortic valve disease. J Mol Med 2009, 87:17-24.
8. Chan K-L: Is aortic stenosis a preventable disease? J Am Coll Cardiol 2003, 42:593-599.
9. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415-1428.
10. Katz R, Wong ND, Kronmal R, et al.: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006, 113:2113-2119.
11. Freeman RV, Otto CM: Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005, 111:3316-3326.
12. Rajamannan NM, GershFB, Bonow RO: Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart 2003, 89:801-805.
13. Rajamannan NM, Otto CM: Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 2004, 110:1180-1182.
14. Rajamannan NM, Subramaniam M, Caira F, et al.: Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005, 112(9 Suppl):I229-I234.
15. Pedersen TR: Intensive lipid-lowering therapy for patients with aortic stenosis. Am J Cardiol 2008, 102:1571-1576.
16. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693-695.
17. Shavelle DM, Takasu J, Budoff MJ, et al.: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-1126.
18. Rosenhek R, Rader F, Loho N, et al.: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
19. Authors/Task Force, Graham I, Atar D, et al.: European guidelines on cardiovascular disease prevention in clinical practice: Executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007 28:2375-2414.
20. Pohle K, Maffert R, Ropers D, et al.: Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
21. Novaro GM, Tiong IY, Pearce GL, et al.: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
22. Moura LM, Ramos SF, Zamorano JL, et al.: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554-561.
23. Bellamy MF, Pellikka PA, Klarich KW, et al.: Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002, 40:1723-1730.
24. Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
25. Rosseb.: Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol 2007, 99:970-973.
26. Chan K-L, Teo K, Tam J, Dumesnil JG: Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 2007, 153:925-931.
27. Helske S, Syvaranta S, Kupari M, et al.: Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006, 27:1495-1504.